<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-106546</identifier>
<setSpec>0212-6567</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Evaluation of the incidence of upper gastrointestinal bleeding in Spain in relation to the taking of anti-ulcer agents</dc:title>
<dc:description xml:lang="en">Objective: To analyse trends in the incidence of hospitalisation due to upper gastrointestinal bleeding (UGB) and the relationship with the prescribing of anti-ulcer agents. Design: Retrospective observational ecological study. Setting: Spanish National Health System (NHS) for the nine years between 1st January 2000 and 31st December 2008. Participants: Inclusion criteria: Patients aged 15 or over hospitalised due to UGB were divided into four age groups: 15-44, 45-64, 65-74 and &amp;#8805;75 years old. Drugs, A02B subgroup, prescribed under the NHS. Exclusion criteria: Prescription of medicines in hospital or public-employee insurance companies. Measurements: Incidence (number of new cases of UGB occurring in one year), Incidence rate (incidence per 100,000 inhabitants), Dispersion rate (number of packets dispensed per year per 100,000 inhabitants), and Hazard ratio (HR, ratio between the rate of the last year over the first year. Annual rates were calculated by the standardised direct method). Data source: Ministry of Health. Results: We identified 110,150 hospital admissions due to UGB (61.17% male, 38.83% female). Values for 95% UGB: Total Mean Incidence Rate (MIR)=34.45 [32.70, 36.20], HR=0.83. Males: MIR=43.07 [40.41, 45.72], HR=0.80 and females: MIR=25.20 [25.18, 27.23], HR=0.88. HR HDA by age group in males: 15-44 years=0.64; 45-64 years=0.74, 65-74years=0.74 and &gt;74years=0.85. Females: 15-44 years=0.82, 45-64years=0.71, 65-74 years=0.3 and &gt;74years=0.89. Drug dispensing (2000-2008): HR proton pump inhibitors=4.43; HR all anti-ulcer agents=3.01. Conclusions: Over nine years the dispensing of anti-ulcer agents by the Spanish National Health System has multiplied without having regard to the evolutionary trend of hospitalisation due to UGB(AU)</dc:description>
<dc:creator>Álvarez-Ibáñez, Carlos</dc:creator>
<dc:creator>Guerra-García, María Mercedes</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Evaluar la evolución del consumo de fármacos antiulcerosos en relación a la tendencia evolutiva de la hospitalización por hemorragia digestiva alta (HDA). Diseño: Estudio observacional retrospectivo ecológico. Emplazamiento: Red pública Sistema Nacional de Salud (SNS) durante 9 años, desde el 1 de enero de 2000 hasta el 31 de diciembre de 2008. Participantes: Criterios inclusión: pacientes con 15 años o más ingresados por HDA, divididos en 4 grupos etarios: 15-44, 45-64, 65-74 y &amp;#8805;75años. Medicamentos facturados con cargo al SNS del subgrupo A02B. Criterios exclusión: prescripción hospitalaria o MUFACE-ISFAS-MUGEJU. Mediciones principales: Incidencia (número nuevos casos acontecidos en un año), tasa incidencia (incidencia/100.000 habitantes) de HDA, tasa consumo (DHD, dosis por habitante/día) y razón de tasas (RT, cociente entre tasas último/primer año). Fuente de datos: Ministerio de Sanidad. Resultados: Se identificaron 110.150 ingresos por HDA (61,17% hombres, 38,83% mujeres). Valores para IC95%. HDA: Tasa incidencia media total (TIM)= 34,45 [32,70; 36,20]; RT=0,83. Hombres: TIM=43,07 [40,41; 45,72]; RT=0,80 y mujeres: TIM=25,20 [25,18; 27,23]; RT=0,88. RT HDA por grupos de edad en hombres: 15-44años=0,64; 45-64años=0,74; 65-74años=0,74 y &gt;74años=0,85. Mujeres: 15-44años=0,82; 45-64=0,71; 65-74años=0,73 y &gt;74años=0,89. En cuanto al incremento de las DHD de los distintos grupos de antiulcerosos durante el periodo de estudio: DHD2008/DHD2000 IBP=4,43; DHD2008/DHD2000 para el total de medicamentos=3,01. Conclusiones: Se detecta un elevado incremento del consumo de fármacos antiulcerosos sin que tenga relación con la tendencia evolutiva de los ingresos por HDA(AU)</dc:description>
<dc:source>Aten Primaria;44(8): 478-484, ago. 2012. tab, graf, ilus</dc:source>
<dc:identifier>ibc-106546</dc:identifier>
<dc:title xml:lang="es">Evolución de la incidencia de la hemorragia digestiva alta en España en relación con el consumo de antiulcerosos</dc:title>
<dc:subject>^d6794</dc:subject>
<dc:subject>^d50295</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d50294</dc:subject>
<dc:subject>^d6623</dc:subject>
<dc:subject>^d52844</dc:subject>
<dc:subject>^d28640^s22045</dc:subject>
<dc:subject>^d28640^s22066</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28571</dc:subject>
<dc:subject>^d13411^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d6916^s22083</dc:subject>
<dc:subject>^d51280</dc:subject>
<dc:subject>^d6623^s22080</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d53386</dc:subject>
<dc:subject>^d908^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201208</dc:date>
</metadata>
</record>
</ibecs-document>
